Kidney International (2007) 72 5 commentar y but also clarify and disseminate information on best practices, and ensure that the health-care system has the capacity to meet the evolving needs of patients once they are identifi ed. We must have reliable tests that accurately discern atrisk populations, evidence-based strategies that truly decrease the occurrence of adverse outcomes in these patients, and the ability to implement these strategies eff ectively. Th e fi ndings of Stevens and his colleagues 5 will help to inform the discussion surrounding CKD identifi cation and management -particularly as further data on outcomes from this and similar initiatives become available in the future.
Tumor necrosis factor-α in cisplatin nephrotoxicity: A homebred foe?
Z Dong 1 and SS Atherton 1 A robust inflammatory response involving tumor necrosis factor-α (TNF-α) is induced during cisplatin nephrotoxicity. Using chimeric models, Reeves and colleagues now demonstrate that resident kidney cells, rather than infiltrating immune cells, are the major producers of TNF-α. Blockade of TNF-α attenuates inflammation and associated kidney injury.
Cisplatin, a widely used chemotherapeutic agent, is used to treat a variety of cancers. A major drawback of this drug is its side eff ects in normal cells and tissues, prominently toxicity in the kidneys. Over 30% of patients develop renal problems during cisplatin treatment, which limits the use and effi cacy of cisplatin in cancer therapy. Th e cellular and molecular mechanism of cisplatin nephrotoxicity is a topic of intense investigation, is very complex, and involves multiple factors and processes, including a robust infl ammatory response and, ultimately, death of renal tubular cells. 1 Tumor necrosis factor-α (TNF-α) is a key player in the infl ammatory response during cisplatin nephrotoxicity. TNF-α production was induced under the pathological condition. [2] [3] [4] Importantly, in TNF-α-deficient mice, the production and secretion of proinfl ammatory cytokines and chemokines were attenuated, and this was associated with amelioration of acute kidney injury and renal failure during cisplatin treatment. Similar observations were shown for TNF-α inhibition by pharmacological inhibitors and neutralizing antibodies. 3 Together, these studies have demonstrated a critical role for TNF-α in mounting the infl ammatory response during cisplatin nephrotoxicity and the ensuing kidney tissue damage and acute renal failure.
Given the role of TNF-α in cisplatin nephrotoxicity, several important questions remain. How does cisplatin induce TNF-α expression? Where is TNF-α produced and by what cells? How does TNF-α stimulate the proinfl ammatory response? By what mechanism does TNF-α induce kidney injury and renal failure? Reeves and colleagues 5 (this issue) have now provided significant insights into these important questions. Specifi cally, they have demonstrated that resident cells of the kidneys, rather than infi ltrating infl ammatory cells, are the major contributors of TNF-α production during cisplatin nephrotoxicity. 5 When considering cytokine and chemokine production under pathological conditions, many of us tend to think about an origin from cells of the immune system. However, in the kidney, there are a variety of cells that can effi ciently produce and secrete cytokines and chemokines. For example, production of TNF-α has been shown in mesangial cells, glomerular cells, endothelial cells, and renal tubular cells. So, is TNF-α produced by infi ltrating immune cells or parenchymal cells of the kidneys? To address this question, Reeves and see original article on page 37 commentar y colleagues 5 created chimeric models in which bone marrow of recipient animals was ablated and then reconstituted with bone marrow derived from wild-type (WT) or TNF knockout (KO) donor mice. Th e reconstitution led to four types of chimeric mice (donor bone marrow genotype → recipient genotype): WT→ WT, KO→WT, WT→KO, and KO→ KO. Aft er cisplatin treatment, the WT recipients (WT→WT and KO→WT) maintained their capacity for TNF-α production, whether WT or TNF-α KO bone marrow was reconstituted. In sharp contrast, TNF-α production was diminished in the TNF-α-defi cient recipients, regardless of WT or KO bone marrow reconstitution. Th us, cisplatininduced TNF-α production in the chimeric models was determined by the genetic background of the recipient and not by the donor bone marrow. Th ese are remarkable fi ndings, which suggest strongly that TNF-α is produced locally by resident cells of the kidneys, rather than by bone marrow-derived immune cells that infi ltrate the organ during cisplatin nephrotoxicity. Notably, WT→ WT and KO→WT chimeras developed severe kidney injury and renal failure aft er cisplatin treatment, whereas WT→ KO and KO→KO chimeras did not. Th is observation, although not surprising or particularly novel in view of the demonstrated involvement of TNF-α in cisplatin nephrotoxicity, indicates that TNF-α produced by the kidneys has an important pathogenic role.
In addition to having an elegant experimental design involving chimeric models, the study by Reeves and colleagues 5 was also very carefully controlled. By transplantation of green fl uorescent protein (GFP)-labeled bone marrow from GFP transgenic mice, they demonstrated a high degree of chimerism in the mouse models. By two-color fl ow cytometry, they showed that bone marrow transplantation did not alter the percentage distribution of leukocyte subtypes. Th ey further demonstrated that circulating immune cells derived from transplanted bone marrow retained their ability to produce TNF-α upon stimulation by phorbol esters and ionomycin, known activators of leukocytes. Th ese are critical controls, which indicate that the lack of TNF-α production by transplanted immune cells during cisplatin nephrotoxicity is not due to their faulty behavior, further supporting the conclusion that TNF-α is produced by resident kidney cells rather than bone marrow-derived immune cells.
Although negating a role of bone marrow-derived immune cells in TNF-α production, the study by Reeves and colleagues 5 does not exclude the involvement of these cells in cisplatin nephrotoxicity. Recent work by Rabb and colleagues 6 demonstrated that, as compared with wild-type animals, T cell-defi cient mice were more resistant to cisplatin nephrotoxicity. Notably, reconstitution of T cells into these animals partially restored their sensitivity to cisplatin injury. 6 Thus, immune cells, particularly the infi ltrating T cells, contribute to the development of renal pathology during cisplatin treatment. Intriguingly, Rabb and colleagues also demonstrated that the production of proinfl ammatory cytokines, including TNF-α, was attenuated in T cell-deficient mice, suggesting a role for T cells in triggering infl ammation and TNF-α production during cisplatin nephrotoxicity. 6 Apparently, there is a discrepancy between the study by Reeves and colleagues and the study by Rabb's group: the former indicates TNF-α production by resident kidney cells, 5 whereas the latter suggests the involvement of infi ltrating T cells. 6 How can these fi ndings be reconciled? One possibility is that, although TNF-α is produced mainly by resident kidney cells, infi ltrating T cells may have a regulatory or stimulatory role. Th is scenario is supported by the observation that T-cell infi ltration occurs very early (within hours) during cisplatin nephrotoxicity. 6 Is there indeed a functional interaction between infi ltrating T cells and resident kidney cells that leads to TNF-α production? How do T cells regulate TNF-α production in kidney cells? Do they secrete cytokines to prime these cells? What specifi c cytokines do they produce? Th ese are important questions for investigation in the future.
Despite the evidence for TNF-α production by resident kidney cells, the exact identity of the responsible cell type(s) has yet to be determined. In the kidneys, mesangial cells, glomerular cells, endothelial cells, and renal tubular cells are all capable of producing TNF-α in response to a variety of stimuli. Reeves commentar y and colleagues showed recently that cisplatin treatment induced modest TNF-α production in cultured proximal tubular cells, which involved gene transcription and mRNA stabilization. 7 Interestingly, in combination with endotoxins, cisplatin dramatically increases TNF-α production and secretion. 8 TNF-α production following the combinatorial treatment seems to involve an intriguing regulation of protein translation via p38 mitogenactivated protein kinase and the translation initiation actor eIF4E. 8 Th ese novel fi ndings suggest that renal tubular cells contribute to TNF-α production during cisplatin nephrotoxicity and related pathological conditions. Certainly, this inference needs to be further established in vivo, ideally with the use of tubular cell-specifi c TNF-α knockout models. If it is proven to be true in the kidneys, then the same tubular cells are producing a noxious molecule (TNF-α) to insult themselves.
Why is it important to identify the cells that produce TNF-α during cisplatin nephrotoxicity? First, this is an essential step toward a fundamental understanding of TNF-α production and infl ammation under the pathological condition. Without knowing what cells are producing TNF-α, it will be very diffi cult, if not impossible, to gain further insights into the underlying molecular mechanisms. Second, many cell types are capable of producing TNF-α, and the signaling pathways regulating TNF-α production in various cells can be quite diff erent. As a result, identifi cation of the TNF-α-producing cell type(s) may focus our eff ort on specifi c pathways in these cells for renoprotection during cisplatin treatment.
How, then, is TNF-α involved in cisplatin nephrotoxicity? As a pleiotropic cytokine, TNF-α induces a variety of cellular responses ranging from infl ammation to cell death. In a given cell, there are two types of TNF-α receptors, TNFR1 and TNFR2. Binding of the receptors activates distinct, but not mutually exclusive, sig naling cascades. Notably, TNFR1 contains a conserved 'death domain, ' which, upon TNF-α ligation, can trigger the formation of a caspase-activation complex, leading to apoptosis. In contrast, TNFR2 does not have the 'death domain' and therefore may not be directly involved in the initiation of apoptosis. During cisplatin-induced nephrotoxicity, renal tubular cells undergo both necrotic and apoptotic cell death. Several years ago, Tsuruya and colleagues showed that proximal tubular cells isolated from TNFR1-defi cient mice were more resistant to cisplatin-induced caspase activation and apoptosis, suggesting the involvement of TNF-α-TNFR1 signaling in tubular-cell apoptosis under the experimental condition. 9 On the other hand, Reeves and colleagues demonstrated the amelioration of cell death in TNFR2-defi cient mice aft er cisplatin treatment. 10 Importantly, this and subsequent studies indicate that a major role of TNF-α is to stimulate the production of proinfl ammatory factors and recruit infl ammatory cells. Consistent with this view, infi ltration of leukocytes into the kidneys is reduced in WT→KO and KO→KO chimeric mice, suggesting that TNF-α produced by resident kidney cells is, indeed, critically important in the inflammatory response. 5 Thus TNF-α may trigger tubular-cell death and tissue damage directly via TNFR1 as well as indirectly by mounting a robust infl ammatory response via TNFR2 (Figure 1) . Nevertheless, while emphasizing the role of TNF-α in our discussion, it is important to recognize that cisplatin nephrotoxicity is a multifactorial process. Th us, although TNF-α is a significant contributing factor to the pathogenesis, it is unlikely to be the only one. Accordingly, pharmacological or genetic suppression of TNF-α and its signaling aff ords significant, but not complete, renoprotection during cisplatin nephrotoxicity. 3, 5, 9, 10 A fascinating area for future study is to decipher how the multiple pathways or mechanisms are integrated to orchestrate a remarkable renal pathology.
Can we inhibit TNF-α to protect the kidneys from cisplatin injury? Th e answer is a sound yes, as demonstrated clearly by Reeves and colleagues. 3, 5, 10 However, it is still not clear whether inhibition of TNF-α is an eff ective strategy for renoprotection during cisplatin-based cancer therapy. An ideal approach for renoprotection during chemotherapy would prevent cell injury and death in the kidneys, yet preserve cell killing in tumors or cancers. Unfortunately, normal tissues (including the kidneys) and cancer cells share many of the mechanisms of cell death in response to cytotoxic insults. It is unclear whether TNF-α mediates cisplatin-induced cytotoxicity in cancers and whether inhibition of TNF-α will diminish the chemotherapeutic eff ects of cisplatin. Investigation in these areas may ultimately lead to the development of TNF-α-targeted strategies for renoprotection during cisplatin therapy.
